Guanxin V for coronary artery disease: A retrospective study.,Biomedicine & Pharmacotherapy

当前位置： X-MOL 学术 › Biomed. Pharmacother. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Guanxin V for coronary artery disease: A retrospective study.
Biomedicine & Pharmacotherapy ( IF 6.9 ) Pub Date : 2020-05-30 , DOI: 10.1016/j.biopha.2020.110280
Bo Liang ₁ , Yuan Qu ₂ , Qing-Feng Zhao ₂ , Ning Gu ₂

Affiliation

Background

Guanxin V (GXV), a traditional herbal mixture, has been widely used in clinical practice for the treatment of coronary artery disease (CAD). This retrospective study was designed to assess the safety and effectiveness of GXV for CAD.

Methods

In our study, December 2006 to January 2009, 101 patients with CAD from Nanjing Hospital of Chinese Medicine Affiliated to Nanjing University of Chinese Medicine were enrolled, of whom 52 patients received GXV plus guideline-recommended medical therapy (GMT) (GXV group), 49 patients received GMT alone (GMT group). The general clinical information, traditional Chinese medicine syndrome score (TSS), the therapeutic effects, 6-minute walk test (6MWT), adverse events, echocardiography, and laboratory information were collected and analyzed pre-and post-treatment.

Results

We did not find differences in the information between the two groups before treatment. Patients in the GXV group had decreased TSS (P < 0.0001) and increased therapeutic effects (P = 0.763) and 6MWT (P < 0.0001) than those in the GMT group and there were no significant differences in safety between the two groups. Moreover, patients in the GXV group improved ejection fraction, cardiac output, and stroke volume (P = 0.2113, 0.0001, 0.0002, respectively), and dropped BNP (P = 0.3856) compared with those in the GMT group.

Conclusions

Superiority in the GXV group for patients with CAD was demonstrated over the GMT group for both the safety and effectiveness endpoints. This suggests that GXV is a potentially safe and effective treatment for CAD patients.

中文翻译：

冠心病V用于冠心病的回顾性研究。

背景

冠心V（GXV）是一种传统的草药混合物，已在临床实践中广泛用于治疗冠状动脉疾病（CAD）。这项回顾性研究旨在评估GXV用于CAD的安全性和有效性。

方法

我们在2006年12月至2009年1月的研究中，招募了南京中医药大学附属南京中医院的101例CAD患者，其中52例接受了GXV联合指南推荐药物治疗（GMT）（GXV组）， 49例患者单独接受GMT治疗（GMT组）。收集治疗前和治疗后的一般临床信息，中医综合症评分（TSS），治疗效果，6分钟步行测试（6MWT），不良事件，超声心动图和实验室信息。

结果

在治疗之前，我们没有发现两组之间的信息差异。与GMT组相比，GXV组患者的TSS降低（P <0.0001），治疗效果提高（P = 0.763）和6MWT（P <0.0001），两组之间的安全性无显着差异。此外，患者在GXV基团而改善射血分数，心输出量，和每搏输出量（P = 0.2113，0.0001，0.0002，分别地），并丢弃BNP（P与那些GMT组比较= 0.3856）。